DARUNAVIR TEVA 800mg tablets medication leaflet

J05AE10 darunavir • Antiinfectives for systemic use | Direct acting antivirals | Protease inhibitors

Darunavir is a protease inhibitor used for the treatment of human immunodeficiency virus (HIV) infection. It works by inhibiting the HIV protease enzyme, which is essential for viral replication, thereby reducing the viral load.

The medication is taken orally, usually once daily, in combination with other antiretroviral drugs. Common side effects include nausea, diarrhea, headaches, and skin rashes.

Darunavir is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. It should also be used with caution in patients with severe hepatic conditions.

This medication is an important option for managing HIV infection, helping to improve patients' quality of life and prevent disease progression.

General data about DARUNAVIR TEVA 800mg

Substance: darunavir

Date of last drug list: 01-06-2025

Commercial code: W64415013

Concentration: 800mg

Pharmaceutical form: tablets

Quantity: 30

Product type: generic

Price: 998.16 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: TEVA OPERATIONS POLAND SP. Z.O.O - POLONIA

Holder: TEVA B.V. - OLANDA

Number: 10542/2018/13

Shelf life: 2 years

Pharmaceutical forms available for darunavir

Concentrations available for darunavir

100mg/ml, 150mg, 300mg, 400mg, 600mg, 75mg, 800mg

Compensation lists for DARUNAVIR TEVA 800mg TEVA

NHP 1.A (C2) - People with HIV/AIDS and post-exposure treatment

Price

Copayment

Patient

998.16 RON

993.98 RON

4.18 RON